| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.089 | 0.05 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.071 | 0.05 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | 0.24 | 0.05 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | -0.072 | 0.05 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | 0.066 | 0.05 |
| mRNA | JQ-1:UNC0638 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.068 | 0.05 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.05 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | 0.097 | 0.05 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.058 | 0.05 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.05 |